Accelerator said Oncofactor was its first investment based on internal intellectual property developed at the group.
Month: June 2011
Corporates harden for Resolve Therapeutics
James Posada, chief executive of Resolve, said: “We are very pleased to close this initial $2m of our series A financing and expect to complete the round with a third, corporate investor in the near future.”
Pulmatrix hits Jack pot
Eva Jack’s move comes after the transition of the US-based team’s other managing directors, Maggie LeFlore and Frank Top, to become venture partners.
FerroKin BioSciences caught by MP
Merchant bank Burrill & Company and venture capital firms Clarus Ventures and Healthcap Ventures also invested in FerroKin BioSciences alongside MP Healthcare Venture Management.
Covagen mops up $7.5m
Covagen spun out of technology university ETH Zurich in 2007 with local drugs group Novartis’ backing and previously raised an undisclosed amount from Novartis Venture Fund and MPH, the corporate venturing unit of Japan’s Mitsubishi Tanabe Pharma (MTP) and Mitsubishi Chemical, in October 2009.
MP Healthcare promotes Mukohira
Mukohira was previously vice-president of MP Healthcare Venture Management, which he started in 2006 as the corporate venturing group of Mitsubishi Tanabe Pharma (MTP) and Mitsubishi Chemical.
Syngenta, Mitsui join Marrone fertiliser deal
Alongside Syngenta Ventures and Mitsui Global Investment were an undisclosed family investment trust and existing venture capital investors Stuart Mill Venture Partners, Contrarian Group, Saffron Hill Ventures, One Earth Capital, Clean Pacific Ventures and Calvert Social Ventures.
InnoCentive flies into challenge
Alongside the Wright Brothers Institute and the US Air Force Research Laboratory, Innocentive will manage theOpen Innovation Pavilion.
SterilMed ascends to leveraged buyout
Great Hill Partners and Primus Capital Funds bought SterilMed, which was also backed by First Analysis, Prism Capital and Sterling Partners as well as Ascension’s corporate venturing unit, for an undisclosed sum.
BioImagene sees Roche exit path
Roche subsidiary Ventana Medical Systems will pay $100m for BioImagene on a debt-free basis.
Quro Science gains $1m
Quro is the third company to get backing from Novartis’ Get Armed To Explore Global Market II (GATE II) Project, which was launched last year with Korean peers.
Yahoo eyes Alibaba resolution
The two companies reached an agreement before Yahoo’s analyst meeting last Wednesday, one of the sources told Reuters.
Alliance Health Networks calls for Physic
Andy Donner, a director at Physic Ventures in San Francisco, will join Alliance’s board and said: “We were attracted to Alliance Health because they are helping to create and foster a culture of consumer-directed health and wellness.”
3M reads Txtr deal
3M New Ventures, the company’s corporate venturing unit, and 3M Electro & Communications Business provided the money that will help Txtr provide access to documents and books wherever they are.